Previous 10 | Next 10 |
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp (TDUP) +7%. Cellectis (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats (SEAT) -6%. Y-mAbs Therapeutic...
Revolution Medicines (NASDAQ:RVMD) is up 13% on Tuesday after the Director Thilo Schroeder bought 168,051 shares at the price range of $18.37 - $21.23 in two separate transactions, latest on Mar. 21. The total value of the combined transaction amounted to $3.4M. Quick look through t...
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American Association f...
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42 nd Annual Health Care Con...
The following slide deck was published by Revolution Medicines, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Revolution Medicines, Inc. 2021 Q4 - Results - Earnings Call Presentation
Revolution Medicines, Inc. (RVMD) Q4 2021 Earnings Conference Call February 28, 2022 04:30 PM ET Company Participants Peg Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Steve Kelsey - President of R&D Jack Anders - Senior Vice President, Finance and...
Revolution Medicines press release (NASDAQ:RVMD): Q4 GAAP EPS of -$0.71 misses by $0.07. Revenue of $9.46M (+8.1% Y/Y) misses by $0.49M. For further details see: Revolution Medicines GAAP EPS of -$0.71 misses by $0.07, revenue of $9.46M misses by $0.49M
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in Global Phase 2 Study Evaluating Combination of RMC-4630 and Lumakras ™ ...
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2021 ...
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncolo...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...